Health & Fitness
Thu, December 1, 2011Wed, November 30, 2011Tue, November 29, 2011Mon, November 28, 2011Sun, November 27, 2011Fri, November 25, 2011Thu, November 24, 2011Wed, November 23, 2011Tue, November 22, 2011Mon, November 21, 2011Sun, November 20, 2011Fri, November 18, 2011Thu, November 17, 2011Wed, November 16, 2011AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
Published in Health and Fitness on Wednesday, November 23rd 2011 at 4:46 GMT by Market Wire
AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health... -- REDWOOD CITY Calif., Nov. 23, 2011 /PRNewswire/ --
AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
REDWOOD CITY Calif., Nov. 23, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: [ ACRX ]), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the 23rd Annual Piper Jaffray Health Care Conference in New York City at the New York Palace Hotel. The presentation is scheduled for Tuesday, November 29 at 9:30 a.m. ET.
The presentation will be webcast live and can be accessed through: [ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ACRX&item_id=4228786 ]. For those who are not available to listen to the live broadcast, the presentation will be archived and available through [ http://www.acelrx.com ].
About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: [ ACRX ]) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the fourth quarter of 2011 under a grant from the US Army Medical Research and Material Command.
SOURCE AcelRx Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.acelrx.com ]
